{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T06:53:09Z","timestamp":1783061589436,"version":"3.54.6"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.radonc.2022.04.017","type":"journal-article","created":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T11:27:03Z","timestamp":1650540423000},"page":"107-113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["MRI-based radiomics to compare the survival benefit of induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma: A multicenter study"],"prefix":"10.1016","volume":"171","author":[{"given":"Hesong","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinxue","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Running","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanbang","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanying","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunrong","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daihong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaosong","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqian","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiuquan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2022.04.017_b0005","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A Cancer J Clin"},{"key":"10.1016\/j.radonc.2022.04.017_b0010","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41571-021-00524-x","article-title":"Nasopharyngeal carcinoma: an evolving paradigm","volume":"18","author":"Wong","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.radonc.2022.04.017_b0015","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(21)01123-5","article-title":"Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial","volume":"398","author":"Chen","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2022.04.017_b0020","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/cncr.31741","article-title":"Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma","volume":"125","author":"Guo","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2022.04.017_b0025","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1002\/cam4.2343","article-title":"Individualized concurrent chemotherapy by pretreatment plasma Epstein-Barr viral DNA in II-III stage nasopharyngeal carcinoma: A propensity score matching analysis using a large cohort","volume":"8","author":"Sun","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.radonc.2022.04.017_b0030","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1089\/gtmb.2018.0304","article-title":"Molecular prognostic value of circulating epstein-barr viral DNA in nasopharyngeal carcinoma: A meta-analysis of 27,235 cases in the endemic area of Southeast Asia","volume":"23","author":"Xie","year":"2019","journal-title":"Genet Test Mol Biomarkers"},{"key":"10.1016\/j.radonc.2022.04.017_b0035","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.00618","article-title":"Predicting progression-free survival using MRI-based radiomics for patients with nonmetastatic nasopharyngeal carcinoma","volume":"10","author":"Shen","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2022.04.017_b0040","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nrclinonc.2017.141","article-title":"Radiomics: the bridge between medical imaging and personalized medicine","volume":"14","author":"Lambin","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.radonc.2022.04.017_b0045","doi-asserted-by":"crossref","first-page":"4259","DOI":"10.1158\/1078-0432.CCR-16-2910","article-title":"Radiomics features of multiparametric MRI as Novel prognostic factors in advanced nasopharyngeal carcinoma","volume":"23","author":"Zhang","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2022.04.017_b0050","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00330-019-06211-x","article-title":"MRI-based radiomics nomogram may predict the response to induction chemotherapy and survival in locally advanced nasopharyngeal carcinoma","volume":"30","author":"Zhao","year":"2020","journal-title":"Eur Radiol"},{"key":"10.1016\/j.radonc.2022.04.017_b0055","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.oraloncology.2019.09.022","article-title":"A multidimensional nomogram combining overall stage, dose volume histogram parameters and radiomics to predict progression-free survival in patients with locoregionally advanced nasopharyngeal carcinoma","volume":"98","author":"Yang","year":"2019","journal-title":"Oral Oncol"},{"key":"10.1016\/j.radonc.2022.04.017_b0060","doi-asserted-by":"crossref","first-page":"103522","DOI":"10.1016\/j.ebiom.2021.103522","article-title":"A deep learning-based radiomic nomogram for prognosis and treatment decision in advanced nasopharyngeal carcinoma: A multicentre study","volume":"70","author":"Zhong","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.radonc.2022.04.017_b0065","unstructured":"National Comprehensive Cancer Network (NCCN) guidelines. Head and Neck Cancers, Version 3, 2021. Accessed April 27, 2021. 2021."},{"key":"10.1016\/j.radonc.2022.04.017_b0070","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.annonc.2020.12.007","article-title":"Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up(\u2020)","volume":"32","author":"Bossi","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2022.04.017_b0075","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1200\/JCO.20.03237","article-title":"Chemotherapy in combination with radiotherapy for definitive-intent treatment of stage II-IVA nasopharyngeal carcinoma: CSCO and ASCO guideline","volume":"39","author":"Chen","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2022.04.017_b0080","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.acra.2020.09.002","article-title":"Pretreatment MRI-derived radiomics may evaluate the response of different induction chemotherapy regimens in locally advanced nasopharyngeal carcinoma","volume":"27","author":"Zhang","year":"2020","journal-title":"Acad Radiol"},{"key":"10.1016\/j.radonc.2022.04.017_b0085","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/jmri.27308","article-title":"MRI-based deep-learning model for distant metastasis-free survival in locoregionally advanced nasopharyngeal carcinoma","volume":"53","author":"Zhang","year":"2021","journal-title":"J Mag Res Imag JMRI"},{"key":"10.1016\/j.radonc.2022.04.017_b0090","doi-asserted-by":"crossref","first-page":"703","DOI":"10.6004\/jnccn.2018.7270","article-title":"Neoadjuvant or adjuvant chemotherapy plus concurrent CRT versus concurrent CRT alone in the treatment of nasopharyngeal carcinoma: a study based on EBV DNA","volume":"17","author":"Liu","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.radonc.2022.04.017_b0095","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1148\/radiol.2020191145","article-title":"The image biomarker standardization initiative: standardized quantitative radiomics for high-throughput image-based phenotyping","volume":"295","author":"Zwanenburg","year":"2020","journal-title":"Radiology"},{"key":"10.1016\/j.radonc.2022.04.017_b0100","first-page":"271","article-title":"Boruta \u2013 a system for feature selection","volume":"101","author":"Kursa","year":"2010","journal-title":"Fund Inform"},{"key":"10.1016\/j.radonc.2022.04.017_b0105","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumour heterogeneity and resistance to cancer therapies","volume":"15","author":"Dagogo-Jack","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.radonc.2022.04.017_b0110","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ccell.2020.03.007","article-title":"Intratumor heterogeneity: the rosetta stone of therapy resistance","volume":"37","author":"Marusyk","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.radonc.2022.04.017_b0115","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa1905287","article-title":"Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma","volume":"381","author":"Zhang","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2022.04.017_b0120","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1158\/1078-0432.CCR-17-2656","article-title":"Induction chemotherapy plus concurrent chemoradiotherapy in endemic nasopharyngeal carcinoma: individual patient data pooled analysis of four randomized trials","volume":"24","author":"Chen","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2022.04.017_b0125","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1200\/JCO.2016.67.4119","article-title":"What is the best treatment of locally advanced nasopharyngeal carcinoma? An individual patient data network meta-analysis","volume":"35","author":"Ribassin-Majed","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2022.04.017_b0130","doi-asserted-by":"crossref","first-page":"104686","DOI":"10.1016\/j.oraloncology.2020.104686","article-title":"Induction versus adjuvant chemotherapy combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A propensity score-matched analysis","volume":"105","author":"Tang","year":"2020","journal-title":"Oral Oncol"},{"key":"10.1016\/j.radonc.2022.04.017_b0135","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1002\/cncr.32972","article-title":"NPC-0501 trial on the value of changing chemoradiotherapy sequence, replacing 5-fluorouracil with capecitabine, and altering fractionation for patients with advanced nasopharyngeal carcinoma","volume":"126","author":"Lee","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2022.04.017_b0140","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","article-title":"Nasopharyngeal carcinoma","volume":"394","author":"Chen","year":"2019","journal-title":"The Lancet"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814022002225?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814022002225?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T05:21:31Z","timestamp":1759123291000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814022002225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":28,"alternative-id":["S0167814022002225"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2022.04.017","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MRI-based radiomics to compare the survival benefit of induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma: A multicenter study","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2022.04.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}